| Date | Title | Description |
| 07.05.2025 | PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics | - |
| 30.12.2024 | Knowledge Intensive EIS Fund IV launch |
We are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund IV, an HMRC-approved EIS Fund. The fourth Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities and resea... |
| 30.12.2024 | PhoreMost – extends Series B to $50m | We are delighted to announce a further investment in PhoreMost, a leading UK biopharmaceutical company unlocking the next generation of drug targets. The University of Cambridge spin-out will use the investment to advance high-value oncolog... |
| 16.09.2024 | PhoreMost: Biopharmaceutical Drug Target Company Raises $50 Million (Series B) | PhoreMost, a leading UK biopharmaceutical company unlocking the next generation of drug targets, announced it has added $12 million to its Series B financing, bringing the total raised to over $50 million. Parkwalk Advisors led this additio... |
| 11.09.2024 | PhoreMost Raises $12M in Series B; Extends Round to $50M | PhoreMost Ltd., a Cambridge, UK-based biopharmaceutical company, added USD $12m to its Series B financing, bringing the total raised to over $50m.
The additional investment was led by Parkwalk Advisors, with participation from existing inve... |
| 11.09.2024 | PhoreMost raises £33M to advance 'Drugging the Undruggable' research | PhoreMost, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, has completed an oversubscribed £33 million Series B investment round.
PhoreMost’s SITESEEKER platform can identify the best new the... |
| 10.09.2024 | PhoreMost and Puraffinity: Two Biotech Innovators Making Waves in Healthcare | In the world of biotechnology, innovation is the lifeblood that fuels progress. Two companies, PhoreMost and Puraffinity, are leading the charge with groundbreaking advancements in drug development and environmental remediation. Both have r... |
| 10.09.2024 | PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes | Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform
Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Am... |
| 21.05.2024 | PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders | - |
| 22.03.2023 | PhoreMost Enhances Drug Discovery Process with CDD Vault | CDD Vault Integrates with SnapGene Server for Web-Based Sharing of Plasmid Information
BURLINGAME, CA, USA, March 22, 2023 /EINPresswire.com/ -- Collaborative Drug Discovery, Inc. (CDD), developer of the research data management platform, C... |
| 02.03.2022 | PhoreMost promotes Dr Neil Torbett to Chief Executive Officer | PhoreMost promotes Dr Neil Torbett to Chief Executive Officer
02-03-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announces the promotion of Dr Neil Torbett to Chief Ex... |
| 18.01.2022 | PhoreMost expands into new facility at Unity Campus, Cambridge | PhoreMost expands into new facility at Unity Campus, Cambridge
18-01-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has relocated its headquarters to ... |
| 12.01.2022 | NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics | NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
12-01-2022
NeoCura Bio-Medical Technology Co Ltd, a leading RNA-based drug research and development company in China, and PhoreMost Limited, the UK-b... |
| 11.01.2022 | NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics | NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
11-01-2022
Shenzhen, China and Cambridge, UK: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development... |
| 15.06.2021 | PhoreMost appoints Christian Dillon as Vice President of Biology | PhoreMost appoints Christian Dillon as Vice President of Biology
15-06-2021
PhoreMost Ltd, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon... |
| 25.03.2021 | PhoreMost’s £33m investment success for disease targets | PhoreMost has completed a £33m Series B investment round. |
| 24.03.2021 | This Cambridge AI drug startup raises £33M to tackle ‘undruggable’ diseases | The Cambridge, UK-based AI drug startup – PhoreMost has recently secured £33m funding in oversubscribed Series B funding round. The funding will push the PLK1 program for the treatment of brain cancer in the clinic within 18 months.
The rou... |
| 23.03.2021 | PhoreMost closes £33M Series B financing | PhoreMost Ltd, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s mos... |
| 23.03.2021 | PhoreMost Raises $46M in Series B Financing | PhoreMost Ltd., a Cambridge, England, UK-based biopharmaceutical company, raised $46m in Series B funding.
The round was led by BGF, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventur... |
| 23.03.2021 | PhoreMost Closes £33M ($46M) Series B Financing | PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s mo... |
| 23.03.2021 | PhoreMost closes £33M Series B financing | PhoreMost closes £33M Series B financing
23-03-2021
PhoreMost Ltd, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B inve... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture M... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline
15-03-2021
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was le... |
| 09.11.2020 | PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration | PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration
09-11-2020
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a le... |
| 12.03.2020 | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards
12-03-2020
Cofinitive are delighted to announce that they have been shortlisted in the upcoming Business Weekly Awards.
The shortlist has listed us as “a growing team of comm... |
| 22.01.2020 | PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical | PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical
22-01-2020
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a... |
| 27.02.2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards
27-02-2019
Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| 15.05.2018 | PhoreMost Completes $15M in Series Funding | PhoreMost, a Cambridge, England, UK-based biopharmaceutical company, completed a $15m (£11m) Series A funding round.
The round was led by current investors Jonathan Milner, Amadeus Capital Partners, Cambridge Enterprise, and cornerstone Par... |
| 15.05.2018 | PhoreMost completes £11M ($15M) Series-A round to enter drug discovery | PhoreMost completes £11M ($15M) Series-A round to enter drug discovery
15-05-2018
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-... |
| 30.04.2018 | Cancer immunotherapy research receives £1m Innovate UK funding | Cancer immunotherapy research receives £1m Innovate UK funding
30-04-2018
PhoreMost Limited and NeoPhore Limited have announced the companies will receive £1 million of funding to support the development of a novel small-molecule cancer imm... |
| 16.11.2017 | NeoPhore Raises £3M in Funding | NeoPhore Ltd, a spin out from Cambridge, UK – based PhoreMost Ltd., focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system, raised £3m in funding.
Sixth Element Ca... |
| 12.10.2016 | PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets | PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets
12-10-2016
PhoreMost Ltd, a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration w... |
| 10.03.2016 | PhoreMost and The Wistar Institute collaborate to identify new druggable targets | PhoreMost and The Wistar Institute collaborate to identify new druggable targets
10-03-2016
PhoreMost Ltd, a Babraham-based biopharmaceutical company focused on increasing the diversity and affordability of novel therapeutics, announced tod... |
| 07.04.2015 | PhoreMost raises £2.5m to identify new druggable targets for therapeutics | PhoreMost raises £2.5m to identify new druggable targets for therapeutics
07-04-2015
PhoreMost Ltd, a biopharmaceutical company and University of Cambridge spin-out founded to identify new druggable targets for cancer and other unmet diseas... |
| 07.04.2015 | PhoreMost raises £2.5m to identify new druggable targets for therapeutics | PhoreMost Ltd, a biopharmaceutical company and University of Cambridge spin-out founded to identify new druggable targets for cancer and other unmet diseases, announced that it has raised £2.5 million in seed funding from Cambridge-based in... |
| 07.04.2015 | PhoreMost Ltd founded to identify new druggable targets for therapeutics | PhoreMost Ltd founded to identify new druggable targets for therapeutics
07-04-2015
PhoreMost Ltd, a biopharmaceutical company focused on increasing the diversity and affordability of novel therapeutics, has been founded to identify new dru... |
| 07.04.2015 | Cambridge biopharma start-up attracts £4m to develop next-gen screening platform | Cambridge biopharma start-up attracts £4m to develop next-gen screening platform
07-04-2015
PhoreMost, a Cambridge-based biopharmaceutical company, has raised £4m in an A round of equity and grant funding, of which the equity is led by Amad... |
| 07.04.2015 | PhoreMost Raises £4M in Funding | PhoreMost, a Cambridge, UK-based biopharmaceutical company, raised £4m in Series A equity and grant funding.
The round was led by Amadeus Capital Partners and Abcam founder Jonathan Milner with participation from Cambridge Enterprise and an... |
| - | EIS: more than financial returns | As institutional investors increasingly regard ESG as an important element of their investment decision, Tom Hopkins, of Parkwalk, wonders whether this element of EIS investment should form part of the client conversation. |
| - | BGF leads £33m investment round into biopharmaceutical company, PhoreMost | BGF has led an oversubscribed £33m investment round into PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®, disease targets. BGF invested £8.5m as part of the deal, which includes new investors X... |
| - | This Cambridge AI drug startup raises £33M to tackle ‘undruggable’ diseases | The Cambridge, UK-based AI drug startup – PhoreMost has recently secured £33m funding in oversubscribed Series B funding round. The funding will push the PLK1 program for the treatment of brain cancer in the clinic within 18 months.
The rou... |
| - | PhoreMost | “Through its SITESEEKER® drug target identification platform, PhoreMost is expanding druggable space. In partnership, we are discovering and developing the …” |
| - | PhoreMost – completes an oversubscribed $46m Series B investment round | Parkwalk are pleased to announce an investment in PhoreMost, as part of a £33m ($46m) Series B funding round, to support progression of PLK1 program, for treatment of brain cancer, into the clinic within 18 months. Parkwalk will remain the ... |
| - | Parkwalk closes PhoreMost investment | We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in PhoreMost as part of a £4m series ‘A’ round of equity and grant funding, of which the equity tranche was led by Amadeus Capital Partne... |
